Eli Lilly's new top dealmaker explains how the company changed its approach to M&A now that it's the most valuable ...

Eli Lilly LLY has pursued a series of acquisitions since early 2026 to strengthen its pipeline and support long-term growth ...

CVS Health does a 180. On May 28, CVS Caremark, the pharmacy benefits manager (PBM) under CVS Health's umbrella, announced it ...

After facing off in the US in a rivalry that made powerful GLP-1 drugs ubiquitous and more affordable, Novo and Lilly are now ...

Eli Lilly (NYSE:LLY | LLY Price Prediction) just grew revenue 55.5% in a single quarter while raising full-year guidance to $82 billion to $85 billion. Mounjaro and Zepbound combined for $12.8 billion ...

By Padmanabhan Ananthan June 3 (Reuters) - Ascidian Therapeutics said on Wednesday it has signed a licensing deal for its ...

Eli Lilly knows that its GLP-1 windfall comes with an end date, so it is acting now to prepare.

Eli Lilly and Boehringer Ingelheim are cutting back on planned investments in Germany in response to a new government ...

Eli Lilly and Company (NYSE:LLY) was among Jim Cramer’s stock calls on Mad Money, as he highlighted several opportunities in ...

CNBC’s Angelica Peebles sits down with Lilly’s President of Oncology and Head of Business Development at the largest global ...

Macro strategist Jordi Visser delivered a striking observation on a recent episode of The Pomp Podcast with Anthony Pompliano ...